Rimegepant Combined With AG Chemotherapy As First-Line Treatment For Metastatic Pancreatic Ductal Adenocarcinoma
Trial statusNot yet recruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorXiuchao Wang
About this trial
This study aims to evaluate the efficacy and safety of Rimegepant combined with AG chemotherapy as first-line treatment for metastatic pancreatic cancer.
Eligibility criteria
Qualifiers
The patient has good compliance, understands the study procedures, and has signed a written informed consent form.
Age ≥ 18 years.
Pathologically or cytologically confirmed pancreatic cancer, with imaging or pathological findings indicating unresectable pancreatic cancer with distant metastasis.
Patients who have not received any prior treatment for pancreatic cancer (including radiotherapy, chemotherapy, or experimental therapy), except for surgical resection.
Disqualifiers
Patients with a history of other malignancies within the past 5 years, except for cured in situ carcinoma or basal cell carcinoma of the skin.
Patients diagnosed with pulmonary fibrosis or interstitial pneumonia within 28 days prior to enrollment.
Patients with refractory pleural effusion or ascites.
Patients with known brain or meningeal metastases.
Trial design
Treatments tested in this trial
- Rimegepant plus Nab-Paclitaxel and Gemcitabine
Treatment groups
30 Participants
are divided into 1 treatment groupLocations
Sponsors and collaborators
Xiuchao Wang
Lead sponsor
Tianjin Medical University Cancer Institute and Hospital
Sponsor institution
Source ClinicalTrials.gov